Your browser doesn't support javascript.
loading
Cryo-EM structure of a RAS/RAF recruitment complex.
Park, Eunyoung; Rawson, Shaun; Schmoker, Anna; Kim, Byeong-Won; Oh, Sehee; Song, Kangkang; Jeon, Hyesung; Eck, Michael J.
Afiliação
  • Park E; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Rawson S; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Schmoker A; Pfizer R&D Center, 3200 Walnut St, Boulder, CO, 80301, USA.
  • Kim BW; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
  • Oh S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Song K; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Jeon H; New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, Chungbuk, 28160, Republic of Korea.
  • Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Nat Commun ; 14(1): 4580, 2023 07 29.
Article em En | MEDLINE | ID: mdl-37516774
ABSTRACT
RAF-family kinases are activated by recruitment to the plasma membrane by GTP-bound RAS, whereupon they initiate signaling through the MAP kinase cascade. Prior structural studies of KRAS with RAF have focused on the isolated RAS-binding and cysteine-rich domains of RAF (RBD and CRD, respectively), which interact directly with RAS. Here we describe cryo-EM structures of a KRAS bound to intact BRAF in an autoinhibited state with MEK1 and a 14-3-3 dimer. Analysis of this KRAS/BRAF/MEK1/14-3-3 complex reveals KRAS bound to the RAS-binding domain of BRAF, captured in two orientations. Core autoinhibitory interactions in the complex are unperturbed by binding of KRAS and in vitro activation studies confirm that KRAS binding is insufficient to activate BRAF, absent membrane recruitment. These structures illustrate the separability of binding and activation of BRAF by RAS and suggest stabilization of this pre-activation intermediate as an alternative therapeutic strategy to blocking binding of KRAS.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Proteínas Proto-Oncogênicas B-raf Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Proteínas Proto-Oncogênicas B-raf Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos